MAPT and Parkinson disease: Here, we, thus, provided a small pilot, case-control study, measuring the content of amyloid peptides (Aβ42, Aβ40) and total tau in serums of patients with PD and exploring their correlations with corresponding CSF levels and main clinical parameters in order to progress in the use of blood-based biomarkers in PD.